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Objectives: Raltegravir pharmacokinetics (PK) show high intra- and inter-patient variability and are also influ-
enced by co-administered substances that alter the gastrointestinal tract environment, such as pH-altering or
metal-containing agents. The aim of this investigation was to develop a population-based absorption, distribu-
tion, metabolism and excretion (ADME) model to investigate the effects of gastrointestinal pH and ingested
magnesium on raltegravir PK.
Methods: In vitro data describing the disposition of raltegravir were obtained from literature sources or gener-
ated by standard methods. Raltegravir (400 mg single dose) PK were simulated in healthy volunteers (50 sub-
jects per group, 20–50 years old, 0.5 proportion female subjects) over a 12 h period.
Results: Simulated raltegravir PK correlated well with data from clinical trials, with a mean deviation in Cmax,
AUC0-12 and Ctrough of ,20%. Solubility of raltegravir in the gastrointestinal tract was increased at higher
luminal pH. Increased intestinal pH and transit time both correlated with higher raltegravir absorption
(P,0.001). Magnesium ingestion reduced raltegravir exposure in simulated subjects, with mean Ctrough
reduced by 32% (P,0.001).
Conclusions: The in vitro– in vivo extrapolation model developed in this study predicted raltegravir PK in virtual
individuals with different gastrointestinal pH profiles. The main PK variables were predicted with good accuracy
compared with reference data, and both luminal pH and magnesium were able to influence drug absorption.
This modelling system provides a tool for investigating the absorption of other drugs, including HIV integrase
inhibitors currently in development, which have also shown interactions with food and metal-containing
products.
Keywords: HIV, pharmacokinetics, integrase inhibitors, permeability, IVIVE
Introduction
Raltegravir showsmarked variability in pharmacokinetics (PK) both
between patients and in the same patient over time. High variabil-
ity in raltegravir Ctrough, withmedian coefficients of variation (CV%)
of 128% and 245% for inter- and intra-patient variability, respect-
ively, has beenobserved in a clinical cohort.1 Similar high variability
has been observed when assessing raltegravir plasma AUC.2 High
intra-individual variability in plasma raltegravir concentrationsand
inconsistent concentration–response relationships have compli-
cated the use of therapeutic drug monitoring and predictive PK
modelling of raltegravir.
The primary route of raltegravir elimination is glucuronidation
via the liver, with around 30% being excreted in urine.3 Metabol-
ism is achieved by UDP-glucuronosyltransferase 1A1 (UGT1A1)
and the drug is neither a substrate for nor an inhibitor of major
cytochrome P450 enzymes.3,4 Atazanavir inhibits UGT1A1,
causing an increase in raltegravir exposure, and rifampicin med-
iates induction of UGT1A1, causing a decrease in raltegravir ex-
posure.5,6 In addition, raltegravir is a weak substrate for the
drug transporters ABCB1, SLC22A6 and SLC15A1 and also inhibits
SLC22A6 in vitro.7 Raltegravir shows uneven distribution in
tissues, with a 2.3-fold higher concentration in vaginal fluid
and a 17-fold lower concentration in CSF compared with
plasma.8,9 These factors do not fully explain the high intra-
patient variability in raltegravir PK, and recent clinical studies
suggest that variation in raltegravir absorption may be more
relevant.10
The PK of raltegravir are influenced by co-administered agents
that raise gastrointestinal (GI) tract pH, such as omeprazole and
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famotidine.11 The rate of disintegration of standard 400 mg ral-
tegravir tablets increases when dissolved at higher pH.12 High-fat
food has been shown to increase raltegravir exposure, which
may be attributable to a fat-induced increase in raltegravir solu-
bility, although in the same study low-fat food decreased ralte-
gravir exposure by an unknown mechanism.13 Furthermore,
antacids containing divalent metals have been shown to
reduce raltegravir Ctrough in healthy subjects, which is believed
to be the result of reduced raltegravir absorption caused by mag-
nesium binding in the lumen.14 These factors may contribute to
the high variability observed in raltegravir PK.
Two drug efficacy studies found that 18% (2 of 11) and 33%
(2 of 6) of patients who failed raltegravir therapy had no evi-
dence of HIV integrase mutations.15,16 These studies suggest
that raltegravir therapy failure may occur independently of HIV
resistance mutations. Raltegravir exposure may be an influencing
factor; however, this was not investigated in the studies. Non-
adherence to treatment may have also contributed to therapy
failure without known resistance mutations. A statistically signifi-
cant correlation between raltegravir exposure and virological re-
sponse was recently demonstrated in patients taking 800 mg
raltegravir once a day, where Ctrough was a predictor of raltegravir
treatment failure.17 These data suggest that raltegravir exposure
contributes to treatment failure, although high HIV RNA at base-
line is the strongest correlate.
A population PKmodel has been published based on data from
six fasted healthy volunteers given a single 400 mg dose of ralte-
gravir, and another model has been published based on the data
from 145 HIV-infected patients and 19 healthy volunteers.10,18
The PK data used in these studies were highly variable and both
concluded that the lack of information on factors with a potential
effect on raltegravir absorption limits the interpretation of the
results. Our previous investigations set out to determine the
impact of drug transporters, pH, cationic metals, raltegravir
tablet breakdown rate and various other factors on raltegravir dis-
position in vitro.7,12,19By incorporating thesemechanistic data into
physiologically based PK (PBPK) models describing physiological
parameters, predictions of potential interactions between ralte-
gravir and co-administered agents may be made a priori.
In vitro– in vivo extrapolation (IVIVE) is the process of using in
vitro physicochemical, permeability and metabolic parameters
to predict in vivo drug characteristics using PK simulation
modelling. The Simcyp population-based absorption, distribution,
metabolism and excretion (ADME) simulator utilizes a ‘bottom-up’
approach that integrates demographic, anatomical, physiological
and drug-specific factors.20 These data are included in PBPK
models, based on physiological compartments that mimic ADME
processes in the human body. This approach can be used to inves-
tigate drug disposition in drug discoveryanddevelopment, such as
PK profiling, drug–drug interactions, bioavailability and drug ex-
posure in special populations.21–23 Moreover, design of a clinical
trial can be optimized using IVIVE by determining how factors
such as sample size, sex ratio and age may influence PK.24 Oral
absorption of a drug can be simulated using different approaches
and taking into account the dynamic interplayof tablet disintegra-
tion, dissolution, solubility, intestinal permeation and, for some
drugs, metabolism. The advanced dissolution, absorption and
metabolism (ADAM) model within Simcyp represents the GI tract
as compartments based upon their physiological and anatomical
characteristics, and the relationship between permeability,
metabolism and dissolution, amongst other factors, can be simu-
lated.25 The aim of this investigation was to develop an IVIVE
Table 1. Input parameters detailing raltegravir properties
Input parameters Value Reference
Physical chemistry
mol. wt 445.16 42
LogPO:W 0.58 19
pKa 6.67 19
B/P 0.6 43
fu 0.17 43
Absorption
Papp pH 7.4,× 1026 cm/s 6.6 19
tablet release rate increased at higher pH 12
solubility–pH profile see Figure S1, available as
Supplementary data at JAC Online
ACD/PhysChem Suite
predicted
Distribution
Vss, L/kg 0.308 Simcyp predicted
Elimination
hepatic CLint, mL/min/10
6
hepatocytes
12.4 18
CLR, L/h 3.6 32
LogPo:w, log partition coefficient between octanol and water (pH 7); B/P, blood to plasma SQ2drug ratio;
fu, free drug fraction in plasma; Papp pH 7.4, apical to basolateral apparent permeability in Caco-2
monolayer at pH 7.4; Vss, volume of distribution; CLint, intrinsic clearance; CLR, renal clearance.
Moss et al.
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model for simulating raltegravir PK and to investigate the role of GI
pH and ingested magnesium using the ADAM model. The model
detailed in this investigation includes data from previous clinical
trials and also in vitro data from previous studies.7,12,19 This com-
binedapproachprovides a systemtodeterminewhich physiologic-
al and drug-based attributes are important in explaining high
raltegravir PK variability.
Methods
In vitro–in vivo extrapolation: drug parameters
Raltegravir PK properties were simulated using the full PBPK model imple-
mented in the Simcyp population-based simulator (Version 11.0, Simcyp
Ltd, UK). Data describing raltegravir physiochemical and pharmacological
properties were added to the model and are summarized in Table 1.
Raltegravir logP, pKa and apparent permeability (Papp) have previously
been determined in-house.19 The dissolution rate of standard 400 mg
film-coated raltegravir tablets was previously determined in a physio-
logical range of pH buffers, and a higher dissolution rate was observed
with increased pH.12 The intrinsic solubility of raltegravir at pH 1–9 was
predicted using the ACD/PhysChem Suite (Toronto, Canada) and data
were added to the IVIVE model (Figure S1, available as Supplementary
data at JAC Online). The volume of distribution and penetration into
tissues were predicted with the full PBPK model within Simcyp using
tissue:plasma partition coefficients predicted using the method of
Poulin and Theil.26 All other factors were obtained from published
literature.
In vitro–in vivo extrapolation: system parameters
All system parameters were taken from the North European Caucasian
population library within Simcyp, with the exception of patient GI pH
values, the ranges of which were obtained from the literature.27–30 All
simulations were performed in five separate population groups, named
Group 1, 2, 3, 4 and 5. These groups contained individuals with the
same physiological attributes as each other (allowing for variation
around the mean) except for mean GI pH values, which increased from
Group 1 to Group 5 (Table 2). All simulated groups consisted of 50%
female subjects. The mean transit times of drug in the different sections
of the GI tract were 0.4, 3.3 and 12 h in the stomach, intestine and colon,
respectively. Each transit time is the mean for a population representative
Table 2. Values for GI pH, raltegravir solubility and raltegravir PK values in each population group after a single 400 mg dose of raltegravir
Group 1 (very low pH) Group 2 (low pH) Group 3 (medium pH) Group 4 (high pH) Group 5 (very high pH)
Stomach
Mean pH 1 2.5 3 5 6
Raltegravir solubility, mg/mL 0.04 0.04 0.04 0.12 0.98
Duodenum
Mean pH 4 4.5 5 6 6.4
Raltegravir solubility, mg/mL 0.04 0.08 0.12 0.98 2.4
Jejunum
Mean pH 4.4 5 5.5 6.8 7
Raltegravir solubility, mg/mL 0.07 0.12 0.33 5.8 8.9
Ileum
Mean pH 6.4 6.8 7.4 7.6 8
Raltegravir solubility, mg/mL 2.4 5.8 20.3 30.0 37.3
Colon
Mean pH 5 5.5 6 6.2 6.5
Raltegravir solubility, mg/mL 0.12 0.33 0.98 1.6 2.9
Cmax, ng/mL 1491 1980 2094 2541 2545
(5th–95th percentile) (821–2836) (1376–3403) (1416–3657) (1676–4383) (1645–4148)
AUC0-12, ng h/mL 5756 7285 8165 10137 11046
(5th–95th percentile) (2486–12335) (3770–14645) (4308–16231) (5321–18916) (6169–19691)
Tmax, h 3.7 3.3 3.2 2.3 2.1
(range) (1.3–5.3) (1.4–4.4) (1.3–4.3) (1.3–3.1) (1.2–2.9)
Ctrough, ng/mL 30.9 51.4 113.2 153.2 188.2
(5th–95th percentile) (8.4–60.9) (21.6–93.6) (58.4–210.1) (87.3–254.7) (95.4–312.8)
fa 0.39 0.49 0.55 0.69 0.75
(5th–95th percentile) (0.16–0.60) (0.26–0.67) (0.34–0.73) (0.45–0.86) (0.54–0.91)
GI pH values are the mean for each group and had a CV% set at 2% when determining pH variation for individuals within a group. Raltegravir solubility
values in each GI segment are the mean for each group and were determined using the ACD/PhysChem Suite (see Figure S1, available as
Supplementary data at JAC Online). Groups 1–5 each contained 50 individuals and represented very low (Group 1) to very high (Group 5) GI pH.
Geometric mean values for Cmax, AUC0-12, Ctrough and fa are given with 5th and 95th percentiles. Median Tmax is given with range.
Effect of pH and metals on simulated raltegravir PK
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and each segment had a CV% of 30% when determining GI transit time
for individuals in a group.
In vitro–in vivo extrapolation: simulation design
Raltegravir (400 mg single dose) PK were simulated in healthy volunteers
(20–50 years old, 0.5 proportion female subjects) over a 12 h period. Fifty
subjects per population group were chosen as the number to use in all
subsequent simulations. Simulated PK results were compared with
actual PK results in published data and were used to calculate simulated
geometric mean values for Cmax (ng/mL), AUC0-12 (ng h/mL), Ctrough (ng/
mL) and fa (fraction of dose absorbed), which were given with 5th and
95th percentiles. Median Tmax (h) was calculated and given with range.
The transit time of raltegravir through the small intestine was collected
from all simulated subjects and any correlation between transit time
and fraction of raltegravir absorbed was determined.
A parallel trial was performed as described above to simulate the
impact of elevated GI magnesium concentrations on raltegravir PK
values. Drug parameters were altered so that the Caco-2 monolayer
Papp of raltegravir was reduced from 6.6 to 3.4 cm/s, which was taken
from previously published data, simulating the impact of 25 mM magne-
sium salt on raltegravir Papp.
19
Statistical analyses
Data were analysed using SPSS 19.0 for Windows. All data were tested for
normality using the Shapiro–Wilk test. An independent t-test was used to
determine the significance of normally distributed data and the Mann–
Whitney U-test was used for non-normal data. A two-tailed P value of
,0.05 was accepted as being statistically significant. The correlation
between simulated raltegravir intestinal transit time (h) and fraction of
drug absorbed was assessed using linear regression analysis. The regres-
sion coefficient (b) was calculated from the linear regression plot and
given with 95% CI.
Results
Impact of GI pH on raltegravir solubility
The impact of pH on raltegravir solubility in the GI tract is shown
in Table 2. A general trend towards increased raltegravir solubility
in all GI segments can be observed by progressing from Group 1
to 5. Between groups the subjects differ only in mean GI pH
values (subjects in Group 1 have very low GI pH, progressing to
Group 5 subjects with very high GI pH); therefore the increase
in raltegravir solubility is likely to be a direct effect of increased
GI pH.
Impact of GI pH and drug intestinal transit time on
raltegravir PK parameters
The impact of GI pH on raltegravir PK parameters in subject
Groups 1 to 5 is also shown in Table 2. Using linear regression
analysis, a general trend towards increased raltegravir exposure
can be observed by progressing from Group 1 (very low GI pH)
to Group 5 (very high GI pH) (b¼0.088 for each group progres-
sion (95% CI¼0.077–0.099, R2¼0.496, P,0.001). Median Tmax
decreased as GI pH increased, which may be influenced by
decreased tablet disintegration time and higher drug solubility
during the earlier stages of the GI tract. Raltegravir intestinal
transit time data were collated from subjects in all groups
tested (50 subjects from each group, 250 subjects in total) and
ranged from 68 to 350 min. Linear regression analysis using in-
testinal transit time (independent variable) and fraction of drug
absorbed (dependent variable) gave a b-value of 0.099 (95%
CI¼0.085–0.113, R2¼0.427), which equates to a 9.9% increase
in fraction of drug absorbed for every 1 h increase in intestinal
transit time (P,0.001).
The fraction of raltegravir absorbed from each GI segment is
shown for subjects in Groups 1, 2, 3, 4 and 5 (Figure 1). Raltegra-
vir absorption via the jejunum was low in subjects from Groups 1,
2 and 3 but became a more substantial route of absorption in
subjects from Groups 4 and 5. Similarly, raltegravir absorption
via the colon was greater in subjects from Groups 4 and
5. Group 5 subjects showed a mean drug fraction absorbed via
the colon of 20% compared with small intestine. A fraction
absorbed of 28% was observed for the hydrophilic drug cefradine
in a separate study using rats.31 As subjects differ only in their
mean GI pH values between groups, the differences in absorption
profiles between groups are likely to be pH related.
Comparison between reference and simulated
raltegravir PK values
Reference PK values (mean+SD) for Cmax (2519+1930 ng/mL),
AUC0-12 (7076+4071 ng h/mL) and Ctrough (71+50 ng/mL) in
Table 3 are the mean of geometric mean values for fasted,
healthy volunteers in selected previous studies.3,11,13,14,18,32 All
reference values displayed high inter-study variability, as shown
by the large standard deviations. Simulated PK values obtained
from subjects in Groups 1 to 5 fell within the range obtained
for reference PK values. Group 2 displayed the best match with
the reference value for AUC0-12 (+3% deviation) and Ctrough
(228% deviation), although the reference Cmax value was most
closely predicted in Group 4 (+1% deviation). Groups 2 and 4 re-
present populations with ‘low’ and ‘high’ GI pH values, respect-
ively (Table 2). When simulated data from all groups were
combined, reference data matched well with simulated geomet-
ric mean Cmax (2091+801 ng/mL; 217% deviation), AUC0-12
(8255+4214 ng h/mL; 17% deviation) and Ctrough (77+79 ng/
mL; 8% deviation).
Impact of magnesium on raltegravir exposure
The impact of magnesium binding on raltegravir PK values in
subject Groups 1 to 5 is shown in Table 4. Geometric mean
ratios (GMRs) were generated that were the ratios of raltegravir
PK values in the presence of elevated GI magnesium concentra-
tions and PK values under the standard conditions given in
Table 2. Simulated Cmax, AUC and Ctrough were all significantly
(P,0.008) reduced by the presence of magnesium in the GI
tract. Raltegravir Tmax was not significantly altered by magne-
sium in Groups 1 (P¼0.49), 2 (P¼0.29) or 3 (P¼0.34) but was
significantly increased in Groups 4 (2.6 h versus 2.3 h,
P¼0.003) and 5 (2.5 h versus 2.1 h, P¼0.001). The increased
Tmax in Groups 4 and 5 are likely a result of an inhibited rate of
raltegravir absorption, caused by reduced tablet breakdown
and lower drug solubility. Data from all groups were combined
and are shown in Figure 2.
Moss et al.
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Figure 1. Mean simulated fraction of raltegravir absorbed (drug absorbed in segment/drug administered)+SD in each GI segment from 50 individuals
from Group 1 (a; very low pH), Group 2 (b; low pH), Group 3 (c; medium pH), Group 4 (d; high pH) and Group 5 (e; very high pH). Table 2 gives details of
GI pH values for each group. D, duodenum; J1, jejunum section 1; J2, jejunum section 2; I1, ileum section 1; I2, ileum section 2; I3, ileum section 3; I4,
ileum section 4; C, colon.
Table 3. Comparison of reference raltegravir PK values obtained from the literature with simulated PK values
Cmax
(ng/mL)
Difference from
reference (%)
AUC0-12
(ng h/mL)
Difference from
reference (%)
Ctrough
(ng/mL)
Difference from
reference (%)
Reference value 2519+1930 — 7076+4071 — 71+50 —
Group 1 1491+582 241% 5756+3092 219% 31+27 256%
Group 2 1980+623 221% 7285+3399 3% 51+31 228%
Group 3 2094+665 217% 8165+3618 15% 113+48 59%
Group 4 2541+808 1% 10137+4300 43% 153+60 115%
Group 5 2545+792 1% 11046+4335 56% 188+78 164%
Combined data 2091+801 217% 8255+4214 17% 77+79 8%
Reference PK values for Cmax, AUC0-12 and Ctrough are the mean+SD values of geometric mean values for fasted, healthy volunteers in selected
previous studies.3,11,13,14,18,32 Each simulated population group contained 50 individuals and geometric mean+SD values are presented for Cmax,
AUC0-12 and Ctrough. The percentage difference of each simulated result to the reference value is given.
Effect of pH and metals on simulated raltegravir PK
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Discussion
The IVIVE model developed in this study predicted the PK of ral-
tegravir in individuals with different GI pH profiles. The main PK
variables were predicted with good accuracy when compared
with reference data. In simulated subjects, increased GI pH
and small intestinal transit time were both associated with
improved raltegravir exposure. Importantly, both factors are
capable of causing intra-patient PK variability in vivo under
certain conditions.33,34
HIV-infected patients, particularly those with advanced
disease progression, have both higher gastric pH and higher
prevalence of gastric microbe colonization than in uninfected
individuals.35,36 The higher gastric pH in HIV-infected patients
may explain why co-administration of omeprazole with raltegra-
vir shows less impact on raltegravir PK in HIV-infected patients
(40% increase in AUC) compared with healthy volunteers
(210% increase in AUC).11,37 However, this hypothesis needs em-
pirical confirmation as GI pH was not directly measured in either
study and there are no published data showing the effect of pH
on raltegravir solubility in vivo. A recent study found a statistically
significant 65% increase (P¼0.01) in raltegravir bioavailability in
females compared with males.10 Females have higher gastric pH
and longer GI transit time than males and the results from our
simulations suggest both of these factors could potentially in-
crease raltegravir exposure.20 However, conflicting reports
suggest no increased raltegravir exposure in females and
factors other than GI pH, such as lower hepatic blood flow and
reduced intestinal P-glycoprotein expression in females, may
better explain any difference in bioavailability.16,32
The simulations showed evidence of decreased raltegravir ex-
posure when individuals were exposed to magnesium in the GI
Table 4. Raltegravir PK values in the presence of elevated magnesium GI concentrations
Group 1 (very low pH) Group 2 (low pH) Group 3 (medium pH) Group 4 (high pH) Group 5 (very high pH)
Cmax, ng/mL 842 1215 1301 1604 1616
5th–95th percentile 447–1611 831–2114 858–2331 1014–2842 1028–2672
GMR 0.56 0.61 0.62 0.63 0.63
P value ,0.001 ,0.001 ,0.001 ,0.001 ,0.001
AUC0-12, ng h/mL 3435.7 4635 5208 6712 7359
Range 1394–7542 2215–9767 2623–10698 3306–13023 3769–13570
GMR 0.60 0.64 0.64 0.61 0.67
P value ,0.001 ,0.001 ,0.001 ,0.001 ,0.001
Tmax, h 3.8 3.5 3.3 2.6 2.5
Range 1.4–5.7 1.4–4.7 1.4–4.5 1.3–3.5 1.3–3.4
Median ratio 1.03 1.06 1.03 1.13 1.19
P value 0.49 0.29 0.34 0.003 0.001
Ctrough, ng/mL 21.9 33.3 66.2 90.3 152.1
5th–95th percentile 4.6–58.2 11.8–63.2 32.5–119.8 48.4–153.5 88.9–253.6
GMR 0.71 0.65 0.58 0.59 0.81
P value 0.008 ,0.001 ,0.001 ,0.001 0.005
fa 0.23 0.31 0.35 0.45 0.50
5th–95th percentile 0.09–0.38 0.15–0.46 0.20–0.50 0.27–0.64 0.31–0.67
GMR 0.59 0.63 0.64 0.65 0.67
P value ,0.001 ,0.001 ,0.001 ,0.001 ,0.001
Each simulated population group contained 50 individuals. Geometric mean values for Cmax, AUC0-12, Ctrough and fa are given SQ3with 5th and 95th
percentiles. Median Tmax (h) is given with range. Values in Table 6 have been divided by corresponding values in Table 4 to calculate the GMRs
(Cmax, AUC0-12, Ctrough and fa) or median ratios (Tmax). P-values were calculated by comparing values between Table 4 and Table 2 SQ4.
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Figure 2. Mean simulated raltegravir plasma concentration–time profile
(black continuous line) with 5th and 95th percentiles (black broken lines)
using combined data from Groups 1–5 (50 subjects from each group,
250 subjects in total). Also shown is the mean simulated raltegravir
plasma concentration–time profile (grey continuous line) with 5th and
95th percentiles (grey broken lines) using combined data from Groups
1–5 following co-ingestion of magnesium (50 subjects from each
group, 250 subjects in total).
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tract. Previously determined permeability values were used in the
simulations, where 25 mM magnesium chloride significantly
reduced raltegravir Papp through Caco-2 monolayers.
19 It must
be acknowledged that the concentration of GI magnesium in
real subjects would fluctuate depending on compartment
volume and magnesium absorption, therefore the intestinal per-
meation of raltegravir would also fluctuate. However, it can be
seen from the model that the rate of raltegravir absorption is a
limiting factor in ultimate exposure. The data from these simula-
tions support the hypothesis that the combined effect of
increased solubility and reduced intestinal permeability could
explain the interaction observed in vivo, where raltegravir Tmax
and Ctrough were lower in subjects co-administered raltegravir
and a magnesium-containing antacid.14
The model created in this study has limitations and the inclu-
sion of further in vitro data could potentially improve the model’s
predictive ability. Elimination of raltegravir from virtual subjects
was determined by whole organ clearance obtained from pub-
lished literature: information about the role of individual meta-
bolic enzymes was not included.18,32 The metabolism of
raltegravir involves enzymes UGT1A1, UGT1A3 and UGT1A9.4 A
model that included the clearance of raltegravir by these individ-
ual enzymes, combined with known phenotypic variations and
expression levels in the virtual population, could provide a
more accurate model for determining raltegravir elimination.
Similarly, the impact of drug transporters on raltegravir exposure
in vivo is not fully understood and was not included in the final
model. The simulated population in our model used physiological
parameters based on data from healthy adults, and the model at
present does not contain a population representing HIV-infected
individuals. Consequently, we could not investigate the influence
of the disease on raltegravir exposure in our model. Most ralte-
gravir PK data predicted by our model were within the range of
those found in clinical data; however, the volume of raltegravir
distribution is substantially lower than in previously published
models.10,18 This discrepancy may be due to the differences in
modelling strategy, where our model utilized in vitro data in
PBPK simulations (bottom-up) and the previously published
models used patient PK data (top-down).
A relationship between raltegravir exposure and treatment
outcome has yet to be conclusively established in the clinic.
There is evidence from studies that raltegravir exposure, when
combined with virological parameters, may play a role in treat-
ment success and drug resistance development.15,17,38 Raltegra-
vir PK profiles occasionally contain multiple peaks or delayed
(.8 h after dosing) peaks and, in an attempt to explain these
peaks, it has been suggested that raltegravir is able to undergo
enterohepatic recirculation via conversion of the raltegravir glu-
curonide metabolite back to the parent form in the intestine,
leading to subsequent reabsorption.10 However, a study in
healthy subjects using radiolabelled raltegravir did not support
the theory, as there was no evidence of drug reabsorption.15 En-
terohepatic recirculation of raltegravir was therefore not included
in the final model. Tablet disintegration rate, which has been
shown to increase in higher pH solutions in vitro, may help
explain unusual raltegravir PK profiles.12,39 Also, preferential ab-
sorption of raltegravir from particular sections of the GI tract de-
pending on GI pH, as demonstrated in our model (Figure 1), may
further explain delayed/multiple drug concentration peaks. These
data remain theoretical as no study has investigated raltegravir
absorption via different sections of the gut in vivo. Further inves-
tigation is needed to determine the extent of raltegravir entero-
hepatic recirculation and these data would have the potential to
further improve our model.
In conclusion, the Simcyp population-based ADME simulator
has been used to create a model simulating raltegravir PK para-
meters with acceptable accuracy to real-life Q1data. The most
useful feature of this model is to investigate ‘what-if’ scenarios
by directly altering subject physiological parameters such as GI
pH and drug absorption rate and observing the effect on ralte-
gravir PK. This also provides a tool for investigating the absorp-
tion of other drugs, such as the second-generation HIV
integrase inhibitors elvitegravir and dolutegravir, which have
also shown interactions with food and metal-containing
products.40,41
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